Unibest

UB891

ProductAripiprazole Tablets
Strength10mg
IndicationsSchizophrenia; Bipolar I disorder; Manic episode; Mixed episode; Major depressive disorder
TherapeuticsPsychiatry
GMPCN - NMPA
RegistrationChina
ModalitiesSmall Molecule

Exclusive Summary

  • Essential Medicine with High Clinical Value: As a WHO Essential Medicine and guideline-recommended first-line treatment, Aripiprazole 10mg is favored globally for its superior metabolic safety profile, serving as the gold standard for maintenance therapy.
  • Massive Chronic Patient Pool: Targeting over 24 million schizophrenia and 40 million bipolar patients worldwide, the lifelong nature of these psychiatric diseases guarantees consistent, high-volume recurring orders for distributors.
  • Superior Cost Competitiveness: With originator patents long expired, leveraging China's highly scalable manufacturing capacity provides overseas partners with aggressive pricing to easily win national tenders and hospital procurements.
  • Complete Regulatory & Compliance Support: Backed by international-standard CTD dossiers and rigorous GMP compliance, enabling distributors to achieve fast-track registration and seamless localization in diverse global markets.

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →